277 related articles for article (PubMed ID: 8012689)
1. Cardiovascular effects of GR117289, a novel angiotensin AT1 receptor antagonist.
Hilditch A; Hunt AA; Gardner CJ; Twissell DJ; Polley J; Travers A; Drew GM; Middlemiss D; Ross BC; Robertson MJ
Br J Pharmacol; 1994 Jan; 111(1):137-44. PubMed ID: 8012689
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological profile of GR117289 in vitro: a novel, potent and specific non-peptide angiotensin AT1 receptor antagonist.
Robertson MJ; Barnes JC; Drew GM; Clark KL; Marshall FH; Michel A; Middlemiss D; Ross BC; Scopes D; Dowle MD
Br J Pharmacol; 1992 Dec; 107(4):1173-80. PubMed ID: 1467838
[TBL] [Abstract][Full Text] [Related]
3. Role of angiotensin AT1 and AT2 receptors in mediating the renal effects of angiotensin II in the anaesthetized dog.
Clark KL; Robertson MJ; Drew GM
Br J Pharmacol; 1993 May; 109(1):148-56. PubMed ID: 8495237
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological effects of GR138950, a novel angiotensin AT1 receptor antagonist.
Hilditch A; Hunt AA; Travers A; Polley J; Drew GM; Middlemiss D; Judd DB; Ross BC; Robertson MJ
J Pharmacol Exp Ther; 1995 Feb; 272(2):750-7. PubMed ID: 7853190
[TBL] [Abstract][Full Text] [Related]
5. Effects of the new angiotensin II type 1 receptor antagonist KRH-594 on several types of experimental hypertension.
Inada Y; Murakami M; Kaido K; Nakao K
Arzneimittelforschung; 1999 Jan; 49(1):13-21. PubMed ID: 10028373
[TBL] [Abstract][Full Text] [Related]
6. Effects of SC-52458, an angiotensin AT1 receptor antagonist, in the dog.
McMahon EG; Yang PC; Babler MA; Suleymanov OD; Palomo MA; Olins GM; Cook CS
Am J Hypertens; 1997 Jun; 10(6):671-7. PubMed ID: 9194514
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of SR 47436 (BMS-186295), a non-peptide angiotensin AT1 receptor antagonist in hypertensive rat models.
Lacour C; Canals F; Galindo G; Cazaubon C; Segondy D; Nisato D
Eur J Pharmacol; 1994 Nov; 264(3):307-16. PubMed ID: 7698170
[TBL] [Abstract][Full Text] [Related]
8. Further investigations into the mechanism of the antihypertensive activity of the angiotensin AT1 receptor antagonist, GR138950.
Hilditch A; Prior HM; Drew GM
Br J Pharmacol; 1996 Jun; 118(3):711-9. PubMed ID: 8762098
[TBL] [Abstract][Full Text] [Related]
9. Prevention by blockade of angiotensin subtype1-receptors of the development of genetic hypertension but not its heritability.
Madeddu P; Anania V; Varoni MV; Parpaglia PP; Demontis MP; Fattaccio MC; Palomba D; Pollock D; Glorioso N
Br J Pharmacol; 1995 Jun; 115(4):557-62. PubMed ID: 7582472
[TBL] [Abstract][Full Text] [Related]
10. Lack of a centrally-mediated antihypertensive effect following acute or chronic central treatment with AT1-receptor antagonists in spontaneously hypertensive rats.
Bunting MW; Widdop RE
Br J Pharmacol; 1995 Dec; 116(8):3181-90. PubMed ID: 8719794
[TBL] [Abstract][Full Text] [Related]
11. In vivo pharmacologic profile of SK-1080, an orally active nonpeptide AT1-receptor antagonist.
Lee BH; Seo HW; Kwon KJ; Yoo SE; Shin HS
J Cardiovasc Pharmacol; 1999 Mar; 33(3):375-82. PubMed ID: 10069671
[TBL] [Abstract][Full Text] [Related]
12. Pharmacological profile of valsartan: a potent, orally active, nonpeptide antagonist of the angiotensin II AT1-receptor subtype.
Criscione L; de Gasparo M; Bühlmayer P; Whitebread S; Ramjoué HP; Wood J
Br J Pharmacol; 1993 Oct; 110(2):761-71. PubMed ID: 8242249
[TBL] [Abstract][Full Text] [Related]
13. Effects of U-97018 on pressor responses to intracerebroventricularly administered angiotensin II in conscious normotensive rats.
Morita O; Kushida H; Kunihara M
J Cardiovasc Pharmacol; 1995 Jun; 25(6):880-7. PubMed ID: 7564332
[TBL] [Abstract][Full Text] [Related]
14. Pharmacology of LR-B/081, a new highly potent, selective and orally active, nonpeptide angiotensin II AT1 receptor antagonist.
Cirillo R; Renzetti AR; Cucchi P; Guelfi M; Salimbeni A; Caliari S; Castellucci A; Evangelista S; Subissi A; Giachetti A
Br J Pharmacol; 1995 Mar; 114(6):1117-24. PubMed ID: 7620700
[TBL] [Abstract][Full Text] [Related]
15. Sympatho-inhibitory actions of irbesartan in pithed spontaneously hypertensive and Wistar-Kyoto rats.
Balt JC; Mathy MJ; Pfaffendorf M; van Zwieten PA
Fundam Clin Pharmacol; 2003 Feb; 17(1):83-91. PubMed ID: 12588634
[TBL] [Abstract][Full Text] [Related]
16. Antihypertensive activity of ABBOTT-81282, a nonpeptide angiotensin II antagonist, in the renal hypertensive rat.
Lee JY; Brune ME; Warner RB; Buckner SB; Winn M; De B; Zydowsky TM; Opgenorth TJ; Kerkman DJ; DeBernardis JF
Pharmacology; 1993 Sep; 47(3):176-87. PubMed ID: 8415868
[TBL] [Abstract][Full Text] [Related]
17. Cardiovascular effects of orally administered ABBOTT-81988, an angiotensin II antagonist, in conscious spontaneously hypertensive rats.
Lee JY; Warner RB; Brune ME; Adler AL; Winn M; De B; Zydowsky TM; Opgenorth TJ; Kerkman DJ; DeBernardis JF
Am J Hypertens; 1994 Nov; 7(11):975-83. PubMed ID: 7848624
[TBL] [Abstract][Full Text] [Related]
18. Functional evidence for the ability of angiotensin AT1 receptor antagonists to cross the blood-brain barrier in rats.
Polidori C; Ciccocioppo R; Pompei P; Cirillo R; Massi M
Eur J Pharmacol; 1996 Jul; 307(3):259-67. PubMed ID: 8836613
[TBL] [Abstract][Full Text] [Related]
19. Effects of the angiotensin AT1 receptor antagonist GRI38950 on haemodynamic function in dogs.
Hunt AA; Hilditch A; Drew GM
J Auton Pharmacol; 1997 Feb; 17(1):1-11. PubMed ID: 9201554
[TBL] [Abstract][Full Text] [Related]
20. Pharmacological characterization of the novel nonpeptide angiotensin II receptor antagonist, BIBR 277.
Wienen W; Hauel N; Van Meel JC; Narr B; Ries U; Entzeroth M
Br J Pharmacol; 1993 Sep; 110(1):245-52. PubMed ID: 8220885
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
